NCT01935128View on ClinicalTrials.gov

Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction

PHASE4CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 3, 2013

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Renal Transplant
Interventions
DRUG

Arm 1 Everolimus/Reduced dose tacrolimus

Immunosuppression drug intervention

Trial Locations (1)

43614

University of Toledo, Health Science Campus, Toledo

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Toledo Health Science Campus

OTHER